The Justice Company Launches Human Rights Screened High Dividend ETF via HANetf White-Label Platform May 13, 2026 The Justice Company has entered the European ETF market with the launch of JURY Global High Dividend UCITS ETF (ticker: JURY). JURY aims to provide exposure to high dividend global equities within clearly defined legal and human-rights boundaries. 10% of the TER will be dedicated to initiatives supporting communities affected by conflict, displacement and systemic oppression.1 The ETF is classified as Article 8 under the Sustainable Finance Disclosure Regulation (SFDR).2 JURY is listed on London Stock Exchange, Xetra, and Borsa Italiana. When you invest in ETFs your capital is at risk.
Allianz Delivers Record Operating Profit in Strong Start to 2026 May 13, 2026 1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net [...]
Going for growth? Labour groups set out competing visions for economic strategy May 12, 2026 Competing groups of Labour MPs have published contrasting growth plans on Tuesday, just as Sir Keir Starmer’s leadership stood on the brink. Both the left-wing Tribune group of MPs and the more centrist Labour Growth Group published pamphlets setting out a number of ideas for growth and tax reform. Tribune’s report, led by former transport [...]
Life after Starmer: What could a new Labour prime minister mean for your money? May 12, 2026 It could soon be time to face the music for Keir Starmer after dozens of MPs called for the Prime Minister to throw in the towel, which could unleash months of speculation and uncertainty. Leading frontrunners for the top job include the Manchester mayor Andy Burnham, former deputy PM Angela Rayner and health secretary Wes [...]
If Labour can’t cut taxes it could at least make them simpler May 12, 2026 Britain’s tax code is now among the most complicated in the world and businesses are left grappling with arbitrary distinctions that consume time and money. The King’s speech is a chance to reset the conversation, says Alan Vallance Ahead of the King’s Speech, the government faces a stark choice. It can continue layering new rules [...]
Wealth managers shares fall amid Starmer political storm May 12, 2026 A host of the City’s top listed wealth managers suffered sharp sell-offs on Tuesday morning as questions over Starmer’s future caused government borrowing costs to soar. Investors have been on alert since fears of a rebellion against Starmer began after last week’s local election results, with the spike in gilt yields now triggering a sell [...]
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook May 12, 2026 SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 [...]
Rayner tells Starmer: Let Burnham back and end ‘toxic culture’ May 10, 2026 Angela Rayner has accused Sir Keir Starmer of a “toxic culture” in in the wake of Labour’s devastating local election defeat, criticising the Prime Minister for blocking Andy Burnham’s return to Westminster. The intervention ramps up the heat on Starmer, whose position was left looking increasingly perilous on Sunday after around 40 Labour MPs called [...]
Janus Henderson Group plc Reports First Quarter 2026 Results May 8, 2026 Solid long-term investment performance, with 66%, 67%, and 68% of assets under management (“AUM”) outperforming relevant benchmarks on a three-, five-, and 10-year basis, respectively, as of March 31, 2026 AUM of US$480 billion as of March 31, 2026, an increase of 29% year over year First quarter 2026 net inflows of US$2.9 billion compared to breakeven net flows in fourth quarter 2025 First quarter 2026 diluted EPS of US$0.59 and adjusted diluted EPS of US$0.90
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results May 7, 2026 Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026